BIO-TECHNE Stock Price, News & Analysis (NASDAQ:TECH)

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE declared a quarterly dividend on Tuesday, August 6th. Shareholders of record on Friday, August 16th will be paid a dividend of $0.32 per share on Friday, August 30th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Thursday, August 15th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) released its earnings results on Tuesday, August, 6th. The biotechnology company reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.17 by $0.08. The biotechnology company earned $191.66 million during the quarter, compared to analysts' expectations of $196.37 million. BIO-TECHNE had a net margin of 13.45% and a return on equity of 13.20%. The company's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the company posted $1.34 EPS. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for BIO-TECHNE.

BIO-TECHNE will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 Wall Street analysts have issued twelve-month price objectives for BIO-TECHNE's shares. Their forecasts range from $165.00 to $270.00. On average, they anticipate BIO-TECHNE's stock price to reach $206.80 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Media coverage about TECH stock has trended negative on Wednesday, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIO-TECHNE earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 799,800 shares, an increase of 8.1% from the August 15th total of 739,700 shares. Based on an average daily trading volume, of 166,700 shares, the short-interest ratio is presently 4.8 days. Approximately 2.1% of the company's stock are sold short. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Celgene (CELG), Gilead Sciences (GILD), AbbVie (ABBV), General Electric (GE), Amgen (AMGN), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH) and Illumina (ILMN).

BIO-TECHNE's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (1.05%), Candriam Luxembourg S.C.A. (0.34%), Stephens Investment Management Group LLC (0.23%), Summit Creek Advisors LLC (0.22%), Envestnet Asset Management Inc. (0.06%) and Palisade Asset Management LLC (0.04%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Norman David Eansor and Robert V Baumgartner. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Stephens Investment Management Group LLC, Riverbridge Partners LLC, Pacer Advisors Inc., Brookstone Capital Management, Palisade Asset Management LLC, Meeder Asset Management Inc., NEXT Financial Group Inc and State of Michigan Retirement System. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Ascension Asset Management LLC, Summit Creek Advisors LLC, State of Alaska Department of Revenue, Envestnet Asset Management Inc., Tributary Capital Management LLC, Navellier & Associates Inc and Clarus Wealth Advisors. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $200.68.

BIO-TECHNE has a market capitalization of $7.60 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]